Current Value
$0.621 Year Return
Current Value
$0.621 Year Return
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
SPB | <0.01% | $1.38B | -33.60% | 3.21% |
MRX | 0.01% | $2.77B | +102.39% | 1.45% |
UNIT | -0.01% | $1.08B | +56.79% | 0.00% |
AMPH | -0.01% | $1.11B | -38.85% | 0.00% |
SXC | 0.01% | $747.47M | -13.69% | 5.48% |
TRGP | -0.01% | $37.70B | +30.07% | 1.86% |
PAGP | 0.02% | $3.86B | -1.41% | 0.00% |
URGN | 0.02% | $597.55M | -13.66% | 0.00% |
GTE | 0.02% | $174.53M | -51.04% | 0.00% |
CLNE | 0.03% | $461.85M | -13.99% | 0.00% |
AIG | -0.03% | $47.47B | +9.59% | 1.98% |
PLNT | -0.03% | $8.96B | +44.48% | 0.00% |
AON | -0.04% | $75.91B | +19.26% | 0.78% |
RPD | 0.04% | $1.54B | -42.80% | 0.00% |
TG | -0.05% | $321.28M | +94.92% | 0.00% |
DSGX | 0.05% | $8.71B | +2.58% | 0.00% |
ATEN | -0.06% | $1.42B | +44.23% | 1.21% |
WEC | 0.06% | $33.11B | +33.56% | 3.32% |
DXYZ | 0.07% | - | - | 0.00% |
ANAB | 0.07% | $701.61M | -4.10% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
GNOM | 17.19% | $44.57M | 0.5% |
RDTE | 15.77% | $137.93M | 0.97% |
FPEI | 14.59% | $1.61B | 0.85% |
BATT | 14.50% | $61.84M | 0.59% |
LIT | 13.77% | $832.26M | 0.75% |
YOLO | 13.59% | $24.65M | 1.12% |
IGBH | 13.53% | $99.93M | 0.14% |
XBI | 13.01% | $4.82B | 0.35% |
CPRJ | 12.81% | $48.26M | 0.69% |
SLX | 12.72% | $71.22M | 0.56% |
JBBB | 12.70% | $1.30B | 0.48% |
KJUL | 12.45% | $119.50M | 0.79% |
XME | 12.35% | $1.89B | 0.35% |
ARKG | 12.21% | $1.02B | 0.75% |
REMX | 12.20% | $308.01M | 0.58% |
CPSM | 12.10% | $64.19M | 0.69% |
IZRL | 12.01% | $116.38M | 0.49% |
IWC | 11.97% | $818.14M | 0.6% |
PICK | 11.94% | $754.80M | 0.39% |
HYSA | 11.94% | $31.23M | 0.55% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
IBMN | -27.57% | $447.08M | 0.18% |
SCHO | -14.39% | $11.03B | 0.03% |
UTWO | -12.72% | $379.52M | 0.15% |
SHY | -12.38% | $23.83B | 0.15% |
VGSH | -12.03% | $22.80B | 0.03% |
XONE | -11.29% | $625.28M | 0.03% |
BAR | -11.09% | $1.11B | 0.1749% |
SGOL | -11.06% | $5.17B | 0.17% |
BTAL | -11.04% | $296.22M | 1.43% |
BUXX | -10.95% | $315.18M | 0.25% |
IAU | -10.94% | $46.70B | 0.25% |
GLDM | -10.91% | $15.74B | 0.1% |
AAAU | -10.79% | $1.54B | 0.18% |
ULST | -10.75% | $654.75M | 0.2% |
GLD | -10.73% | $100.19B | 0.4% |
OUNZ | -10.56% | $1.73B | 0.25% |
BSCR | -10.54% | $3.68B | 0.1% |
IBTI | -9.75% | $1.06B | 0.07% |
BSCP | -9.67% | $3.28B | 0.1% |
FXY | -9.65% | $816.38M | 0.4% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
HCSG | 36.50% | $1.09B | +40.90% | 0.00% |
PRPO | 28.19% | $17.08M | +125.94% | 0.00% |
PEGA | 26.93% | $9.01B | +80.22% | 0.23% |
ATXS | 26.30% | $323.37M | -36.33% | 0.00% |
ALEC | 26.10% | $149.99M | -65.99% | 0.00% |
RGNX | 23.41% | $434.35M | -20.33% | 0.00% |
BASE | 23.20% | $1.34B | +35.74% | 0.00% |
NG | 23.04% | $1.82B | +29.48% | 0.00% |
ARWR | 22.57% | $2.33B | -32.59% | 0.00% |
PGEN | 22.38% | $475.24M | +9.52% | 0.00% |
SMMT | 21.77% | $16.80B | +228.30% | 0.00% |
GXO | 21.75% | $5.78B | +2.31% | 0.00% |
GPRO | 21.39% | $116.59M | -47.14% | 0.00% |
AMED | 21.27% | $3.15B | -1.38% | 0.00% |
OVID | 20.96% | $23.50M | -56.03% | 0.00% |
MGNX | 20.85% | $87.06M | -67.14% | 0.00% |
CMPS | 20.21% | $313.83M | -46.09% | 0.00% |
AMLX | 20.01% | $585.66M | +271.19% | 0.00% |
CDLX | 19.98% | $94.50M | -78.34% | 0.00% |
ATI | 19.86% | $12.08B | +49.09% | 0.00% |
Yahoo
Insiders who acquired US$1.10m worth of Relmada Therapeutics, Inc.'s ( NASDAQ:RLMD ) stock at an average price of...
Yahoo
Dr. Pruthi brings vast clinical development experience advancing novel therapies for NMIBC to Relmada and the NDV-01 program Phase 3 trial for NDV-01 expected to begin in H1 2026 CORAL GABLES, Fla., June 17, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced the appointment of Raj S. Pruthi, MD as Chief Medical Off
Yahoo
Relmada Therapeutics Inc (RLMD) reports significant progress in its product pipeline with promising Phase II data, despite facing financial hurdles in Q1 2025.
SeekingAlpha
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q1 2025 Earnings Call May 12, 2025 4:30 PM ETCompany ParticipantsBrian Ritchie - Investor RelationsSergio Traversa...
Yahoo
Positive initial Phase 2 proof-of-concept data for NDV-01 at AUA 2025 showing a 90% overall response rate at any time in non-muscle invasive bladder cancer (US prevalence 600K patients) The Phase 2 study for NDV-01 continues with updates at 6, 9 and 12 month data follow-up over the course of 2025. Plans to start Phase III registration trial in H1 2026 Expecting to initiate a Phase 2 study for sepranolone in Prader-Willi syndrome in H1 2026 (US prevalence 20,000 patients) Conference Call and Webc
Yahoo
CORAL GABLES, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, or “the Company”), a clinical-stage biotechnology company committed to advancing innovative breakthrough therapies, today announced plans to host a conference call and webcast on Monday, May 12, 2025 at 4:30 PM ET to discuss financial results for the first quarter ended March 31, 2025 and recent business progress. Conference Call and Webcast Information: Date: Monday, May 12, 2025 at 4:30 PM
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
TFI | -0.02% | $3.22B | 0.23% |
EMB | -0.03% | $13.84B | 0.39% |
BILZ | -0.17% | $821.74M | 0.14% |
NYF | -0.19% | $892.18M | 0.25% |
DIAL | 0.22% | $367.24M | 0.29% |
JPMB | -0.23% | $46.52M | 0.39% |
SUSC | -0.25% | $1.17B | 0.18% |
PCY | -0.27% | $1.17B | 0.5% |
VCEB | -0.28% | $867.21M | 0.12% |
CANE | -0.31% | $10.37M | 0.29% |
IGEB | -0.31% | $1.26B | 0.18% |
MINO | -0.33% | $320.08M | 0.39% |
FLCO | 0.33% | $599.65M | 0.35% |
PGHY | 0.34% | $177.30M | 0.35% |
IDLV | 0.35% | $400.39M | 0.25% |
LMBS | 0.36% | $5.11B | 0.64% |
INDA | 0.36% | $10.07B | 0.62% |
WEAT | 0.37% | $117.15M | 0.28% |
OVT | 0.39% | $49.48M | 0.8% |
CTA | 0.40% | $1.06B | 0.76% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CCRN | -40.64% | $429.13M | -3.89% | 0.00% |
CYCN | -37.40% | $10.59M | +46.35% | 0.00% |
PMT | -16.46% | $1.15B | -3.78% | 12.05% |
CME | -13.46% | $99.39B | +40.68% | 3.86% |
OTIS | -13.22% | $39.39B | +3.41% | 1.60% |
PHYS.U | -12.40% | - | - | 0.00% |
ADC | -12.26% | $7.93B | +16.41% | 4.21% |
ZCMD | -12.11% | $29.55M | -8.59% | 0.00% |
HRB | -11.98% | $7.48B | -0.13% | 2.66% |
CSTE | -11.84% | $66.69M | -59.79% | 0.00% |
AMT | -11.46% | $104.32B | +14.40% | 3.00% |
BRFS | -11.38% | $5.74B | -10.64% | 0.00% |
KMB | -11.35% | $43.92B | -3.75% | 3.75% |
LII | -10.63% | $21.37B | +10.06% | 0.79% |
HLF | -10.34% | $990.97M | -14.35% | 0.00% |
CHT | -10.28% | $36.42B | +25.70% | 3.21% |
PCRX | -10.01% | $1.07B | +7.16% | 0.00% |
FENG | -9.82% | $12.58M | -16.79% | 0.00% |
WSO | -9.46% | $18.50B | -5.00% | 2.41% |
DPZ | -9.01% | $15.55B | -8.72% | 1.44% |